Table 2.
Patient characteristics by participation in the initial survey
| Patient characteristics | Participated n = 4280 |
Did not participate n = 9308 |
Standardized differenceb | Odds ratioc (95% CI) |
|---|---|---|---|---|
|
Age: Mean (SD) Median (Min to Max) |
49.7 (15.1) 49.1 (19–95) |
48.5 (17.3) 47.7 (19–102) |
0.07 | NA |
| Age groups | ||||
| 18–45 | 1648 (38.5) | 4225 (45.4) | 0.14 | REF |
| > 45–65 | 1866 (43.6) | 3261 (35.0) | 0.18 | 1.9 (1.7–2.1) |
| Over 65 | 766 (17.9) | 1822 (19.6) | 0.04 | 1.6 (1.5–1.8) |
| Sex | ||||
| Female | 2304 (53.8) | 4559 (49.0) | 0.10 | REF |
| Male | 1976 (46.2) | 4749 (51.0) | 1.0 (0.9–1.1) | |
| IBD type | ||||
| CD | 2182 (51.0) | 4735 (50.9) | < 0.01 | REF |
| UC | 1938 (45.3) | 4180 (44.9) | 0.01 | 1.1 (1.0–1.1) |
| Unspecified | 160 (3.7) | 393 (4.2) | 0.03 | 0.9 (0.7–1.1) |
| Biologic treatment a | ||||
| Yes | 1136 (26.5) | 2232 (24.0) | 0.06 | REF |
| No (bio-naïve) | 3144 (73.5) | 7076 (76.0) | 1.1 (1.0–1.2) | |
| SES | ||||
| 1 to 5 (low) | 769 (18.0) | 2491 (26.8) | 0.21 | REF |
| 6 to 7 (moderate) | 1708 (39.9) | 3468 (37.3) | 0.05 | 1.2 (1.1–1.3) |
| 8 to 10 (high) | 1792 (41.9) | 3326 (35.7) | 0.13 | 1.1 (1.0–1.2) |
| Missing | 11(0.3) | 23 (0.2) | 0.02 | 1.0 (0.5–2.1) |
| Digital usage count (past year) | ||||
| None | 38 (0.9) | 1450 (15.6) | 0.55 | 0.1 (0.1–0.2) |
| Low (1 to 19) | 519 (12.1) | 2573 (27.6) | 0.40 | REF |
| Moderate (20 to 46) | 1004 (23.5) | 1926 (20.7) | 0.07 | 2.7 (2.4–3.0) |
| High (47 to 94) | 1218 (28.5) | 1823 (19.6) | 0.21 | 3.6 (3.2–4.1) |
| Very high (95 or more) | 1501 (35.1) | 1536 (16.5) | 0.43 | 5.8 (5.1–6.6) |
Values are n (column %) unless noted otherwise
Total percentages may range between 99.9–100.1 due to rounding
aBiologic treatment was defined as having purchased at least one biologic medication including: Vedolizumab, Infliximab, Adalimumab, Ustekinumab, Golimumab, Tofacitinib, or Certolizumab
bThe absolute standardized differences was calculated as described by Austin [18] Standardized differences below 0.2 were considered non-meaningful
CI confidence level, NA not applicable, REF reference group, SES Socioeconomic status, CD Crohn's disease; UC Ulcerative Colitis
cOdds ratios are mutually adjusted for all variables in the table, estimated from a multivariable logistic regression that modeled the likelihood of participating compared to the reference group